Evert Bosdriesz

How fast-growing bacteria robustly tune their ribosome concentration to approximate growth-rate maximization

Maximization of growth rate is an important fitness strategy for bacteria. Bacteria can achieve this by expressing proteins at optimal concentrations, such that resources are not wasted. This is exemplified for Escherichia coli by the increase of its ribosomal protein‐fraction with growth rate, which precisely matches the increased protein synthesis demand. These findings and others have led to the hypothesis that E. coli aims to maximize its growth rate in environments that support growth. However, what kind of regulatory strategy is required for a robust, optimal adjustment of the ribosome concentration to the prevailing condition is still an open question. In the present study, we analyze the ppGpp‐controlled mechanism of ribosome expression used by E. coli and show that this mechanism maintains the ribosomes saturated with its substrates. In this manner, overexpression of the highly abundant ribosomal proteins is prevented, and limited resources can be redirected to the synthesis of other growth‐promoting enzymes. It turns out that the kinetic conditions for robust, optimal protein‐partitioning, which are required for growth rate maximization across conditions, can be achieved with basic biochemical interactions. We show that inactive ribosomes are the most suitable ‘signal’ for tracking the intracellular nutritional state and for adjusting gene expression accordingly, as small deviations from optimal ribosome concentration cause a huge fractional change in ribosome inactivity. We expect to find this control logic implemented across fast‐growing microbial species because growth rate maximization is a common selective pressure, ribosomes are typically highly abundant and thus costly, and the required control can be implemented by a small, simple network.

How Biochemical Constraints of Cellular Growth Shape Evolutionary Adaptations in Metabolism

Evolutionary adaptations in metabolic networks are fundamental to evolution of microbial growth. Studies on unneeded-protein synthesis indicate reductions in fitness upon nonfunctional protein synthesis, showing that cell growth is limited by constraints acting on cellular protein content. Here, we present a theory for optimal metabolic enzyme activity when cells are selected for maximal growth rate given such growth-limiting biochemical constraints. We show how optimal enzyme levels can be understood to result from an enzyme benefit minus cost optimization. The constraints we consider originate from different biochemical aspects of microbial growth, such as competition for limiting amounts of ribosomes or RNA polymerases, or limitations in available energy. Enzyme benefit is related to its kinetics and its importance for fitness, while enzyme cost expresses to what extent resource consumption reduces fitness through constraint-induced reductions of other enzyme levels. A metabolic fitness landscape is introduced to define the fitness potential of an enzyme. This concept is related to the selection coefficient of the enzyme and can be expressed in terms of its fitness benefit and cost.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

BRAF(V600E) mutant melanomas treated with inhibitors of the BRAF and MEK kinases almost invariably develop resistance that is frequently caused by reactivation of the mitogen activated protein kinase (MAPK) pathway. To identify novel treatment options for such patients, we searched for acquired vulnerabilities of MAPK inhibitor-resistant melanomas. We find that resistance to BRAF+MEK inhibitors is associated with increased levels of reactive oxygen species (ROS). Subsequent treatment with the histone deacetylase inhibitor vorinostat suppresses SLC7A11, leading to a lethal increase in the already-elevated levels of ROS in drug-resistant cells. This causes selective apoptotic death of only the drug-resistant tumor cells. Consistently, treatment of BRAF inhibitor-resistant melanoma with vorinostat in mice results in dramatic tumor regression. In a study in patients with advanced BRAF+MEK inhibitor-resistant melanoma, we find that vorinostat can selectively ablate drug-resistant tumor cells, providing clinical proof of concept for the novel therapy identified here.

Evolutionary pressures on microbial metabolic strategies in the chemostat

Protein expression is shaped by evolutionary processes that tune microbial fitness. The limited biosynthetic capacity of a cell constrains protein expression and forces the cell to carefully manage its protein economy. In a chemostat, the physiology of the cell feeds back on the growth conditions, hindering intuitive understanding of how changes in protein concentration affect fitness. Here, we aim to provide a theoretical framework that addresses the selective pressures and optimal evolutionary-strategies in the chemostat. We show that the optimal enzyme levels are the result of a trade-off between the cost of their production and the benefit of their catalytic function. We also show that deviations from optimal enzyme levels are directly related to selection coefficients. The maximal fitness strategy for an organism in the chemostat is to express a well-defined metabolic subsystem known as an elementary flux mode. Using a coarse-grained, kinetic model of Saccharomyces cerevisiae’s metabolism and growth, we illustrate that the dynamics and outcome of evolution in a chemostat can be very counter-intuitive: Strictly-respiring and strictly-fermenting strains can evolve from a common ancestor. This work provides a theoretical framework that relates a kinetic, mechanistic view on metabolism with cellular physiology and evolutionary dynamics in the chemostat.

Binding proteins enhance specific uptake rate by increasing the substrate–transporter encounter rate

Microorganisms rely on binding‐protein assisted, active transport systems to scavenge for scarce nutrients. Several advantages of using binding proteins in such uptake systems have been proposed. However, a systematic, rigorous and quantitative analysis of the function of binding proteins is lacking. By combining knowledge of selection pressure and physiochemical constraints, we derive kinetic, thermodynamic, and stoichiometric properties of binding‐protein dependent transport systems that enable a maximal import activity per amount of transporter. Under the hypothesis that this maximal specific activity of the transport complex is the selection objective, binding protein concentrations should exceed the concentration of both the scarce nutrient and the transporter. This increases the encounter rate of transporter with loaded binding protein at low substrate concentrations, thereby enhancing the affinity and specific uptake rate. These predictions are experimentally testable, and a number of observations confirm them.

Identifying biomarkers of anti-cancer drug synergy using multi-task learning

Combining anti-cancer drugs has the potential to increase treatment efficacy. Because patient responses to drug combinations are highly variable, predictive biomarkers of synergy are required to identify which patients are likely to benefit from a drug combination. To aid biomarker identification, the DREAM challenge consortium has recently released data from a screen containing 85 cell lines and 167 drug combinations. The main challenge of these data is the low sample size: per drug combination, a median of 14 cell lines have been screened. We found that widely used methods in single drug response prediction, such as Elastic Net regression per drug, are not predictive in this setting. Instead, we propose to use multi-task learning: training a single model simultaneously on all drug combinations, which we show results in increased predictive performance. In contrast to other multi-task learning approaches, our approach allows for the identification of biomarkers, by using a modified random forest variable importance score, which we illustrate using artificial data and the DREAM challenge data. Notably, we find that mutations in MYO15A are associated with synergy between ALK / IGFR dual inhibitors and PI3K pathway inhibitors in triple-negative breast cancer. Author summary Combining drugs is a promising strategy for cancer treatment. However, it is often not known which patients will benefit from a particular drug combination. To identify patients that are likely to benefit, we need to identify biomarkers, such as mutations in the tumor’s DNA, that are associated with favorable response to the drug combination. In this work, we identified such biomarkers using the drug combination data released by the DREAM challenge consortium, which contain 85 tumor cell lines and 167 drug combinations. The main challenge of these data is the extremely low sample size: a median of 14 cell lines have been screened per drug combination. We found that traditional methods to identify biomarkers for monotherapy response, which analyze each drug separately, are not suitable in this low sample size setting. Instead, we used a technique called multi-task learning to jointly analyze all drug combinations in a single statistical model. In contrast to existing multi-task learning algorithms, which are black-box methods, our method allows for the identification of biomarkers. Notably, we find that, in a subset of breast cancer cell lines, MYO15A mutations associate with response to the combination of ALK / IGFR dual inhibitors and PI3K pathway inhibitors.

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models

Activation of the mitogen-activated protein kinase (MAPK) pathway is frequent in cancer. Drug development efforts have been focused on kinases in this pathway, most notably on RAF and MEK. We show here that MEK inhibition activates JNK-JUN signaling through suppression of DUSP4, leading to activation of HER Receptor Tyrosine Kinases. This stimulates the MAPK pathway in the presence of drug, thereby blunting the effect of MEK inhibition. Cancers that have lost MAP3K1 or MAP2K4 fail to activate JNK-JUN. Consequently, loss-of-function mutations in either MAP3K1 or MAP2K4 confer sensitivity to MEK inhibition by disabling JNK-JUN-mediated feedback loop upon MEK inhibition. In a panel of 168 Patient Derived Xenograft (PDX) tumors, MAP3K1 and MAP2K4 mutation status is a strong predictor of response to MEK inhibition. Our findings suggest that cancers having mutations in MAP3K1 or MAP2K4, which are frequent in tumors of breast, prostate and colon, may respond to MEK inhibitors. Our findings also suggest that MAP3K1 and MAP2K4 are potential drug targets in combination with MEK inhibitors, in spite of the fact that they are encoded by tumor suppressor genes.

Modelling signalling networks from perturbation data

Motivation Intracellular signalling is realized by complex signalling networks, which are almost impossible to understand without network models, especially if feedbacks are involved. Modular Response Analysis (MRA) is a convenient modelling method to study signalling networks in various contexts. Results We developed the software package STASNet (STeady-STate Analysis of Signalling Networks) that provides an augmented and extended version of MRA suited to model signalling networks from incomplete perturbation schemes and multi-perturbation data. Using data from the Dialogue on Reverse Engineering Assessment and Methods challenge, we show that predictions from STASNet models are among the top-performing methods. We applied the method to study the effect of SHP2, a protein that has been implicated in resistance to targeted therapy in colon cancer, using a novel dataset from the colon cancer cell line Widr and a SHP2-depleted derivative. We find that SHP2 is required for mitogen-activated protein kinase signalling, whereas AKT signalling only partially depends on SHP2. Availability and implementation An R-package is available at https://github.com/molsysbio/STASNet. Supplementary information Supplementary data are available at Bioinformatics online.

Low affinity membrane transporters can increase net substrate uptake rate by reducing efflux

Cells require membrane-located transporter proteins to import nutrients from the environment. Many organisms have several similar transporters for the same nutrient, which differ in their affinity. Typically, high affinity transporters are expressed when substrate is scarce and low affinity ones when substrate is more abundant. The benefit of using low affinity transporters when high affinity ones are available has so far remained unclear. Here, we investigate two hypotheses. First, it was previously hypothesized that a trade-off between the affinity and the maximal catalytic rate explains this phenomenon. We find some theoretical and experimental support for this hypothesis, but no conclusive evidence. Secondly, we propose a new hypothesis: for uptake by facilitated diffusion, at saturating extracellular substrate concentrations, lowering the affinity enhances the net uptake rate by reducing the substrate efflux rate. As a consequence, there exists an optimal, external substrate concentration dependent transporter affinity. An in silico analysis of glycolysis in Saccharomyces cerevisiae shows that using the low affinity HXT3 transporter instead of the high affinity HXT6 enhances the steady-state flux by 36%. We tried to test this hypothesis using yeast strains expressing a single glucose transporter that was modified to have either a high or a low affinity. Due to the intimate and reciprocal link between glucose perception and metabolism, direct experimental proof for this hypothesis remained inconclusive in our hands. Still, our theoretical results provide a novel reason for the presence of low affinity transport systems which might have more general implications for enzyme catalyzed conversions.

Comparative Network Reconstruction using mixed integer programming

Motivation Signal‐transduction networks are often aberrated in cancer cells, and new anti‐cancer drugs that specifically target oncogenes involved in signaling show great clinical promise. However, the effectiveness of such targeted treatments is often hampered by innate or acquired resistance due to feedbacks, crosstalks or network adaptations in response to drug treatment. A quantitative understanding of these signaling networks and how they differ between cells with different oncogenic mutations or between sensitive and resistant cells can help in addressing this problem. Results Here, we present Comparative Network Reconstruction (CNR), a computational method to reconstruct signaling networks based on possibly incomplete perturbation data, and to identify which edges differ quantitatively between two or more signaling networks. Prior knowledge about network topology is not required but can straightforwardly be incorporated. We extensively tested our approach using simulated data and applied it to perturbation data from a BRAF mutant, PTPN11 KO cell line that developed resistance to BRAF inhibition. Comparing the reconstructed networks of sensitive and resistant cells suggests that the resistance mechanism involves re‐establishing wild‐type MAPK signaling, possibly through an alternative RAF‐isoform. Availability and implementation CNR is available as a python module at https://github.com/NKI‐CCB/cnr. Additionally, code to reproduce all figures is available at https://github.com/NKI‐CCB/CNR‐analyses. Supplementary information Supplementary data are available at Bioinformatics online.